What IGF-1 LR3 is, and what has actually been published about it
In short
IGF-1 LR3 is a potent analogue of insulin-like growth factor 1, modified to escape its binding proteins. The most recent study administering it, in mice, remodelled amyloid plaques but failed to preserve cognitive function. No study in people has been located.
IGF-1 LR3 is an analogue of insulin-like growth factor 1. Its name describes the two modifications it carries: an arginine at position 3 and a long extension at the amino end. The purpose of both is the same, reducing its binding to the IGF-1 binding proteins, which leaves more free fraction and makes the analogue more potent than the original molecule [2].
Outside biomedical research, it has been used for decades as a cell culture medium supplement, and indeed part of the recent literature is about producing it recombinantly at scale [1].
What the most recent study administering it says
It is a 2025 paper in Alzheimer model mice, with the compound given intranasally. The result is in the title of the article, and it is worth reading in full:
it remodelled amyloid plaques in the cerebral cortex, but failed to preserve cognitive function [2].
It is a mixed result, published honestly by its authors, and a good reminder that changing a marker is not the same as changing the outcome that matters.
What has not been found
This product is sold, in practice, on its supposed effect on muscle. A PubMed search on 10 September 2026 with the corresponding terms — long R3 analogue, muscle hypertrophy, binding proteins — returned no results.
With the scope stated: it does not appear in that channel. It is not a claim about all the world's literature, but it is one about the index where it would be if it existed in indexed journals.
A 2026 review places IGF-1 LR3 among the compounds appearing in the self-administration protocols circulating online, and ranks that whole group by evidence tier, from randomised-trial data to a complete absence of human studies [3]. That same review collects, for the whole family, reported endocrine and metabolic adverse effects, plus a concern about mitogenic potential it describes as biologically plausible but unproven.
This page describes published literature. It is not medical information, it does not describe a therapeutic use, and it does not replace any healthcare professional.
What to look at when comparing suppliers
- Identity confirmation for the batch: it is a small protein, not a short peptide, and its folding matters. The right mass does not guarantee correct folding.
- HPLC purity for the specific batch, with a certificate you can read before buying.
- A real cold chain. It is among the most temperature-sensitive compounds in the catalogue.
References
- [1] Lu Z. et al. (2023). Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Appl Microbiol Biotechnol. PMID 37261455 View source
- [2] Engel M.G. et al. (2025). Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. J Alzheimers Dis. PMID 39610283 View source
- [3] Dominikowski A. et al. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. PMID 42395176 View source
This page reports what has been published in the scientific literature about a research molecule. It is not medical information, it does not describe a therapeutic use, and it does not replace any healthcare professional. The product is sold strictly for in vitro research.
